N-Acetylcysteine in Schizophrenia: A Convergent Redox-Based Approach to Therapeutic Potential.
4 affiliations
- 1August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain.
- 2Clínic Foundation for Biomedical Research (FCRB), 08036 Barcelona, Spain.
- 3Department of Fundamental and Clinical Nursing, Faculty of Nursing, University of Barcelona, 08907 Barcelona, Spain.
- 4CSMA Dreta de l'Eixample, Fundació CPB Serveis Salut Mental, 08025 Barcelona, Spain.
Abstract
Schizophrenia (SCZ) remains one of the most disabling psychiatric disorders, in large part because current antipsychotics (APs) inadequately address negative symptoms and cognitive deficits. Converging evidence implicates a set of interconnected mechanisms, NMDAR hypofunction, oxidative stress, and a possible low-grade neuroimmune activation, that converge on parvalbumin-positive GABAergic interneuron dysfunction, the likely substrate of these refractory symptom domains. N-Acetylcysteine (NAC) is an adjunctive candidate because it may act on several of these pathways: it replenishes glutathione (GSH), restores redox balance, and modulates glutamatergic transmission, while its immunomodulatory effects remain poorly characterized in SCZ. This comprehensive review synthesizes evidence from preclinical models and clinical trials, showing that NAC produces replicated but modest benefits for negative symptoms and cognitive function, with inconsistent effects on positive symptoms. Notably, null findings in clinical-high-risk and treatment-resistant populations, together with a single exploratory subgroup analysis in early psychosis in which a peripheral redox index (erythrocyte glutathione peroxidase activity) was associated with positive-symptom response, raise the hypothesis that NAC efficacy may depend on a pre-existing, measurable antioxidant deficit. Adequately powered, biomarker-enriched trials that stratify patients by redox status are therefore needed to determine whether NAC is an effective targeted therapy for a mechanistically defined SCZ subgroup. Such trials would resolve whether the modest effect sizes observed in unselected populations reflect true but limited efficacy or dilution by enrolment of redox-normal patients unlikely to benefit.
Related
- Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia
- Hyperventilation Unmasks Convergent Aperiodic EEG Vulnerability in Seizure Disorder and Schizophrenia
- Convergent multidimensional neural phenotypes in human patients and schizophrenia-relevant mouse models identify reduced recurrent excitation in cortical circuits
- Meta-analysis of brain and blood transcriptional signatures of neuroimmune dysregulation in Schizophrenia: convergent evidence for excessive complement system activity and CX3CL1-CX3CR1 axis disruption
- Glutathione-related redox imbalance and cognitive impairment in drug-naïve, first-episode schizophrenia: a focus on GSSG
BibTeX
@article{rubiocontreras2026nacetylcysteine,
title = {{N-Acetylcysteine in Schizophrenia: A Convergent Redox-Based Approach to Therapeutic Potential.}},
author = {Enric Rubio-Contreras and Alonso Pérez-Toribio and Patricia Álvaro and Ana M Cosialls and Constanza Morén},
journal = {Antioxidants (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/antiox15101277},
url = {https://europepmc.org/article/MED/42939851},
note = {CC BY},
}
RIS
TY - JOUR
TI - N-Acetylcysteine in Schizophrenia: A Convergent Redox-Based Approach to Therapeutic Potential.
AU - Enric Rubio-Contreras
AU - Alonso Pérez-Toribio
AU - Patricia Álvaro
AU - Ana M Cosialls
AU - Constanza Morén
PY - 2026
DA - 2026/10/02
JO - Antioxidants (Basel, Switzerland)
DO - 10.3390/antiox15101277
UR - https://europepmc.org/article/MED/42939851
AB - Schizophrenia (SCZ) remains one of the most disabling psychiatric disorders, in large part because current antipsychotics (APs) inadequately address negative symptoms and cognitive deficits. Converging evidence implicates a set of interconnected mechanisms, NMDAR hypofunction, oxidative stress, and a possible low-grade neuroimmune activation, that converge on parvalbumin-positive GABAergic interneuron dysfunction, the likely substrate of these refractory symptom domains. N-Acetylcysteine (NAC) is an adjunctive candidate because it may act on several of these pathways: it replenishes glutathione (GSH), restores redox balance, and modulates glutamatergic transmission, while its immunomodulatory effects remain poorly characterized in SCZ. This comprehensive review synthesizes evidence from preclinical models and clinical trials, showing that NAC produces replicated but modest benefits for negative symptoms and cognitive function, with inconsistent effects on positive symptoms. Notably, null findings in clinical-high-risk and treatment-resistant populations, together with a single exploratory subgroup analysis in early psychosis in which a peripheral redox index (erythrocyte glutathione peroxidase activity) was associated with positive-symptom response, raise the hypothesis that NAC efficacy may depend on a pre-existing, measurable antioxidant deficit. Adequately powered, biomarker-enriched trials that stratify patients by redox status are therefore needed to determine whether NAC is an effective targeted therapy for a mechanistically defined SCZ subgroup. Such trials would resolve whether the modest effect sizes observed in unselected populations reflect true but limited efficacy or dilution by enrolment of redox-normal patients unlikely to benefit.
SN - 2076-3921
ER -